[
  {
    "topic_or_construct": [
      "Treatment-resistant depression"
    ],
    "measured_by": [
      "\u22652 antidepressant switches after adequate dose and duration"
    ],
    "justification": "\u201cTreatment-resistant depression (TRD) is widely used as an outcome variable, broadly defined as \u22652 switches between antidepressant drugs prescribed for an adequate duration in individuals diagnosed with a depressive disorder.\u201d"
  },
  {
    "topic_or_construct": [
      "Treatment-resistant depression"
    ],
    "measured_by": [
      "electroconvulsive therapy (ECT) use"
    ],
    "justification": "\u201cIn other studies, TRD has been defined based on use of electroconvulsive therapy (ECT) derived from register data or medical records.\u201d"
  },
  {
    "topic_or_construct": [
      "Antidepressant treatment stability / effectiveness"
    ],
    "measured_by": [
      "continued antidepressant prescription for \u226590 days"
    ],
    "justification": "\u201cUsing RWD, treatment stability has been defined as continued prescription of an antidepressant, for example for \u226590 days, as a proxy for treatment effectiveness.\u201d"
  },
  {
    "topic_or_construct": [
      "Treatment-resistant schizophrenia"
    ],
    "measured_by": [
      "clozapine use"
    ],
    "justification": "\u201cAs it is primarily used for treatment-resistant SCZ, clozapine has been widely used in research as a proxy measure for non-response/treatment resistance both using clinical data and RWD.\u201d"
  },
  {
    "topic_or_construct": [
      "Treatment-resistant schizophrenia"
    ],
    "measured_by": [
      "antipsychotic polypharmacy (\u22652 antipsychotics for \u226590 days)"
    ],
    "justification": "\u201cUse of clozapine or antipsychotic polypharmacy defined as \u22652 antipsychotics for \u226590 days has been used as a proxy for treatment-resistant SCZ in a Swedish register study.\u201d"
  },
  {
    "topic_or_construct": [
      "Treatment-resistant schizophrenia"
    ],
    "measured_by": [
      "prescription of a third antipsychotic after two trials \u22656 weeks"
    ],
    "justification": "\u201cIn a study using eHRs, treatment-resistant SCZ was defined as either use of clozapine or prescription of a third new antipsychotic after two different antipsychotic prescriptions for \u22656 weeks.\u201d"
  },
  {
    "topic_or_construct": [
      "Ultra-treatment-resistant schizophrenia"
    ],
    "measured_by": [
      "readmission after discharge on clozapine"
    ],
    "justification": "\u201cUsing data from eHRs, ultra-treatment-resistant SCZ (i.e. non-response to clozapine) has been defined as readmission following an inpatient episode where the patient was discharged on clozapine.\u201d"
  },
  {
    "topic_or_construct": [
      "Lithium response"
    ],
    "measured_by": [
      "Alda scale"
    ],
    "justification": "\u201cPrevious studies investigating treatment outcomes in BIP mainly include studies of lithium response assessed by the Alda scale (\u2018Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder\u2019).\u201d"
  },
  {
    "topic_or_construct": [
      "Lithium non-response"
    ],
    "measured_by": [
      "hospitalization or second psychotropic drug within 6 months of lithium initiation"
    ],
    "justification": "\u201cIn a nationwide register-based study from Denmark, lithium nonresponse was defined as hospitalization at a psychiatric ward or prescription of a second psychotropic drug within six months after starting lithium treatment\u2026\u201d"
  },
  {
    "topic_or_construct": [
      "Mood stabilizer treatment failure"
    ],
    "measured_by": [
      "time to discontinuation or add-on of another psychotropic medication"
    ],
    "justification": "\u201cUsing eHR data, treatment failure of mood stabilizers has been defined as time to discontinuation of the medication or add-on of another mood stabilizer, antipsychotic, antidepressant or benzodiazepine.\u201d"
  }
]